Simon Delagrave

Simon Delagrave

Company: Ring Therapeutics

Job title: SVP


Investigating the Promise of Anellovectors to Address Tropism, Immunogenicity & Redosing in Gene Therapy 5:45 pm

Sequencing of human anelloviruses reveals a vast genetic diversity with potential implications for gene therapy, such as: Generating more targeted gene delivery vectors Enabling re-dosing and improving the therapeutic index of gene therapies An update will be provided on Ring Therapeutics’ efforts in developing AnellovectorsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.